AI Market Mood: Stock Dashboard
XAIR
Fundamental
Company: Beyond Air Inc
Sector: Healthcare
Industry: Medical Devices
Country: USA
Exchange: NASD
Index: -
P/E: -
EPS (ttm): -5.42
Insider Own: 5.88%
Shs Outstand: 10.53M
Perf Week: 8.93%
Market Cap: 8.14M
Forward P/E: -
EPS next Y: -1.75
Insider Trans: 0.00%
Shs Float: 9.91M
Perf Month: -3.77%
Enterprise Value: 14.05M
PEG: -
EPS next Q: -0.54
Inst Own: 13.95%
Short Float: 1.15%
Perf Quarter: -19.01%
Income: -31.00M
P/S: 1.18
EPS this Y: 72.16%
Inst Trans: -1.13%
Short Ratio: 0.02
Perf Half Y: -70.83%
Sales: 6.92M
P/B: 0.80
EPS next Y Percentage: 54.47%
ROA: -87.43%
Short Interest: 0.11M
Perf YTD: 6.47%
Book/sh: 0.97
P/C: 0.46
EPS next 5Y: 51.60%
ROE: -240.75%
52W High: 5.84 -86.77%
Perf Year: -83.20%
Cash/sh: 1.70
P/FCF: -
EPS past 3/5Y: 25.75% 17.29%
ROIC: -99.00%
52W Low: 0.65 18.74%
Perf 3Y: -99.41%
Dividend Est.: -
EV/EBITDA: -
Sales past 3/5Y: - 21.66%
Gross Margin: 1.83%
Volatility W: 8.18%
Volatility M: 7.71%
Perf 5Y: -99.35%
Dividend TTM: -
EV/Sales: 2.03
EPS Y/Y TTM: 74.30%
Oper. Margin: -419.51%
ATR (14): 0.07
Perf 10Y: -
Dividend Ex-Date: -
Quick Ratio: 4.77
Sales Y/Y TTM: 129.04%
Profit Margin: -447.75%
RSI (14): 46.88
Recom: 1.40
Dividend Gr. 3/5Y: - -
Current Ratio: 5.12
EPS Q/Q: 71.23%
SMA20: 2.55%
Beta: 0.54
Target Price: 7.75
Payout: -
Debt/Eq: 2.91
Sales Q/Q: 104.66%
SMA50: -14.26%
Rel Volume: 0.03
Prev Close: 0.81
Employees: 61
LT Debt/Eq: 2.86
Earnings: Feb 13 BMO
SMA200: -57.68%
Avg Volume: 7.55M
Price: 0.77
IPO: Sep 23, 2016
Option/Short: No / Yes
EPS/Sales Surpr.: -13.26% 1.89%
Trades:
Volume: 235,155
Change: -4.27%
Technical:
Latest News:
New AI drug discovery powerhouse Xaira rises with $1B in funding - Fierce Biotech very bullish
XAIR
Summary: Xaira Therapeutics has emerged with $1 billion in committed funding and an impressive team led by prominent figures in the biotech industry, including Marc Tessier-Lavigne, Ph.D., and David Baker, Ph.D. The company aims to revolutionize drug discovery by combining machine learning, data generation, and therapeutic product development.
Full article2024-04-24T14:00:06Z